Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IMS China Forecasts Rapid Growth In China’s Pharmaceutical Market Despite Global Slowdown

This article was originally published in PharmAsia News

Executive Summary

IMS China recently predicted that the global pharmaceutical market will experience a further slowdown this year, and that the source of market growth has shifted from the U.S. and EU to emerging markets. Emerging markets will have huge potential in the next 10 years, contributing one-third of overall growth in the global pharmaceutical industry. China is positioned to be the largest emerging market in the next five years. Last year, the Chinese market increased by 26 percent - the highest rate worldwide - and this year it is expected to expand by more than 20 percent. Many multinational pharmaceutical companies have crafted strategies aimed at raising their investment in the country and at expanding from first-tier urban centers to second- and third-tier cities. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071132

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel